BBR Partners LLC Trims Stock Position in Colgate-Palmolive (NYSE:CL)

BBR Partners LLC trimmed its stake in Colgate-Palmolive (NYSE:CL) by 29.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,081 shares of the company’s stock after selling 2,556 shares during the period. BBR Partners LLC’s holdings in Colgate-Palmolive were worth $590,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Main Street Research LLC increased its stake in shares of Colgate-Palmolive by 1.5% during the second quarter. Main Street Research LLC now owns 6,939 shares of the company’s stock valued at $673,000 after buying an additional 100 shares during the period. BLB&B Advisors LLC increased its position in Colgate-Palmolive by 2.5% during the 2nd quarter. BLB&B Advisors LLC now owns 4,337 shares of the company’s stock valued at $421,000 after purchasing an additional 104 shares during the period. ZWJ Investment Counsel Inc. raised its holdings in shares of Colgate-Palmolive by 3.1% in the 2nd quarter. ZWJ Investment Counsel Inc. now owns 3,591 shares of the company’s stock valued at $349,000 after purchasing an additional 109 shares in the last quarter. Hexagon Capital Partners LLC lifted its position in shares of Colgate-Palmolive by 9.5% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,274 shares of the company’s stock worth $124,000 after purchasing an additional 110 shares during the period. Finally, RFG Advisory LLC boosted its stake in shares of Colgate-Palmolive by 2.1% during the second quarter. RFG Advisory LLC now owns 5,411 shares of the company’s stock valued at $525,000 after purchasing an additional 112 shares in the last quarter. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Trading Down 0.2 %

Shares of NYSE:CL opened at $108.52 on Friday. The firm has a market capitalization of $89.03 billion, a price-to-earnings ratio of 34.34, a price-to-earnings-growth ratio of 3.73 and a beta of 0.39. The business’s 50 day moving average price is $100.86 and its 200-day moving average price is $94.28. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70. Colgate-Palmolive has a 1 year low of $67.62 and a 1 year high of $109.30.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.04. Colgate-Palmolive had a net margin of 14.21% and a return on equity of 470.19%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $5 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. On average, equities research analysts forecast that Colgate-Palmolive will post 3.57 earnings per share for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Friday, July 19th were given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date of this dividend was Friday, July 19th. Colgate-Palmolive’s dividend payout ratio (DPR) is 63.29%.

Wall Street Analysts Forecast Growth

Several analysts have commented on CL shares. Wells Fargo & Company increased their price target on shares of Colgate-Palmolive from $92.00 to $97.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 10th. HSBC reissued a “hold” rating on shares of Colgate-Palmolive in a research report on Friday, July 26th. Citigroup lifted their price target on shares of Colgate-Palmolive from $103.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Morgan Stanley increased their price objective on Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Colgate-Palmolive from $104.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $102.53.

Insider Buying and Selling

In other news, Director Martina Hundmejean sold 2,313 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the transaction, the director now directly owns 11,755 shares in the company, valued at approximately $1,220,874.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Martina Hundmejean sold 2,313 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $103.86, for a total transaction of $240,228.18. Following the transaction, the director now owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sally Massey sold 15,850 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total transaction of $1,636,988.00. Following the sale, the insider now owns 13,942 shares of the company’s stock, valued at $1,439,929.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,490 shares of company stock worth $4,486,063. 0.34% of the stock is owned by insiders.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.